title: Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization.
abstract: DNA amplifications are important mechanisms for proto-oncogene activation. Comparative genomic hybridization (CGH) to metaphase chromosome preparations has revealed amplifications in 10-20% of B-cell lymphomas (B-NHL). We analysed a series of 16 aggressive non-Hodgkin lymphomas by the new approach termed Matrix-CGH (M-CGH) using genomic DNA microarrays as hybridization target. For M-CGH, a dedicated B-cell lymphoma chip was constructed containing 496 genomic targets covering oncogenes, tumor suppressor genes as well as chromosome regions frequently altered in B-NHL. In 10 of 16 samples a total of 15 DNA amplifications were identified. The amplicons included BCL2, REL, CCND1, CCND2, JAK2, FGF4 and MDM2. Four of the 15 amplifications remained undetected by chromosomal CGH. The respective amplicons mapped to bands 2p13, 9p13-p21 and 12q24 and, were confirmed by fluorescence in situ hybridization. Furthermore, for four genomically amplified genes real-time quantitative reverse transcription polymerase chain reaction revealed elevated mRNA expression levels. These data show the superior diagnostic sensitivity of the newly developed diagnostic tool. As only a small portion of the genome (approximately 1.5%) has been analysed by the present DNA array, it is likely that gene amplifications are much more common in aggressive lymphomas than previously assumed.
authors.affiliation: Abt Innere Medizin III, Medizinische Klinik der Universität Ulm, Germany.
authors.forename: Swen
authors.initials: S
authors.lastname: Wessendorf
authors.forename: Carsten
authors.initials: C
authors.lastname: Schwaenen
authors.forename: Holger
authors.initials: H
authors.lastname: Kohlhammer
authors.forename: Dirk
authors.initials: D
authors.lastname: Kienle
authors.forename: Gunnar
authors.initials: G
authors.lastname: Wrobel
authors.forename: Thomas F E
authors.initials: TF
authors.lastname: Barth
authors.forename: Michelle
authors.initials: M
authors.lastname: Nessling
authors.forename: Peter
authors.initials: P
authors.lastname: Möller
authors.forename: Hartmut
authors.initials: H
authors.lastname: Döhner
authors.forename: Peter
authors.initials: P
authors.lastname: Lichter
authors.forename: Martin
authors.initials: M
authors.lastname: Bentz
mesh_terms: D002051:Burkitt Lymphoma / Q000235:genetics*; D002874:Chromosome Mapping; D003199:Computer Systems; D004273:DNA, Neoplasm / Q000235:genetics*; D005784:Gene Amplification; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D016393:Lymphoma, B-Cell / Q000235:genetics*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics*; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics*; D008677:Metaphase; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D009693:Nucleic Acid Hybridization / Q000379:methods*; D020411:Oligonucleotide Array Sequence Analysis; D000090063:Proto-Oncogene Mas; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D004273:DNA, Neoplasm; C000715470:MAS1 protein, human; D009363:Neoplasm Proteins; D000090063:Proto-Oncogene Mas; D012333:RNA, Messenger; D012334:RNA, Neoplasm